Brokers Offer Predictions for Guardant Health Q4 Earnings

Guardant Health, Inc. (NASDAQ:GH) – Equities researchers at Leerink Partnrs increased their Q4 2024 earnings per share (EPS) estimates for Guardant Health in a research report issued on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now expects that the company will post earnings per share of ($0.73) for the quarter, up from their prior forecast of ($0.76). The consensus estimate for Guardant Health’s current full-year earnings is ($3.44) per share. Leerink Partnrs also issued estimates for Guardant Health’s Q1 2025 earnings at ($0.62) EPS, Q2 2025 earnings at ($0.64) EPS, Q3 2025 earnings at ($0.60) EPS, Q4 2025 earnings at ($0.69) EPS, FY2025 earnings at ($2.54) EPS and FY2026 earnings at ($2.86) EPS.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. The company had revenue of $191.48 million during the quarter, compared to the consensus estimate of $170.49 million. During the same quarter in the prior year, the business earned ($0.73) earnings per share. The firm’s revenue for the quarter was up 33.9% compared to the same quarter last year.

Several other research analysts also recently commented on GH. JPMorgan Chase & Co. lifted their target price on Guardant Health from $48.00 to $50.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Leerink Partners reduced their price target on Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. Sanford C. Bernstein reduced their price target on Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a research note on Wednesday, October 30th. Barclays started coverage on Guardant Health in a research note on Thursday. They issued an “overweight” rating and a $60.00 price target for the company. Finally, The Goldman Sachs Group boosted their price target on Guardant Health from $32.00 to $36.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Sixteen equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $41.81.

Guardant Health Trading Down 2.9 %

Shares of NASDAQ GH opened at $47.21 on Thursday. Guardant Health has a 12 month low of $15.81 and a 12 month high of $49.86. The stock has a 50 day moving average of $35.26 and a 200-day moving average of $29.53. The company has a market capitalization of $5.83 billion, a P/E ratio of -11.13 and a beta of 1.28.

Institutional Investors Weigh In On Guardant Health

Hedge funds and other institutional investors have recently bought and sold shares of the company. JNBA Financial Advisors bought a new stake in shares of Guardant Health in the 3rd quarter valued at about $26,000. R Squared Ltd bought a new stake in shares of Guardant Health in the 4th quarter valued at about $26,000. Ashton Thomas Securities LLC bought a new stake in shares of Guardant Health in the 3rd quarter valued at about $34,000. Quarry LP bought a new stake in shares of Guardant Health in the 2nd quarter valued at about $44,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Guardant Health in the 2nd quarter valued at about $71,000. Institutional investors own 92.60% of the company’s stock.

Insider Transactions at Guardant Health

In related news, Director Musa Tariq sold 2,320 shares of the business’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $35.00, for a total transaction of $81,200.00. Following the sale, the director now owns 2,676 shares in the company, valued at $93,660. The trade was a 46.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Meghan V. Joyce sold 2,896 shares of the business’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total value of $86,590.40. Following the sale, the director now owns 7,648 shares in the company, valued at $228,675.20. This represents a 27.47 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 5,548 shares of company stock valued at $179,782. Corporate insiders own 5.50% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.